The Microbiome in (Non-) Obese Pregnancy and Pregnancy Outcomes (PROMOTE)
Status
Conditions
Treatments
Details and patient eligibility
About
This research aims to elucidate an underlying mechanism of maternal obesity induced pregnancy and longterm health complications for mothers and their offspring.
Full description
With the increasing global prevalence of obesity, pregnancy problems related to maternal obesity are increasingly occurring. Microbial gut symbiosis plays an important role in health, with dysbiosis being associated with diseases such as obesity. Of interest are pregnancy, dietary patterns and pre- or probiotics that affect the composition of the gut microbiome. The microbiome itself can influence many physiological processes, such as immune responses (production of microbial products) and the nutrient-dependent one-carbon metabolism. It is hypothesized that gut dysbiosis, due to maternal obesity, during pregnancy can be considered an endogenous chronic stressor causing impaired immune response and carbon metabolism. Both processes result in excessive oxidative stress, detrimental to cell replication, differentiation and epigenetic programming of maternal and infant tissues. Together, these biological disturbances contribute to placental and vascular dysfunction, leading to an increased risk of preeclampsia or gestational diabetes mellitus. Vertical (during pregnancy) and horizontal (during delivery) transmission of gut dysbiosis from mother to newborn and epigenetic placental and foetal changes may ultimately lead to macrosomia and obesity in children. Therefore, the differences between the gut and vaginal microbiome, maternal and fetal immune responses and one-carbon metabolism in obese versus normal-weight pregnant women will be analysed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Participation in Predict study
- Preconceptional women who wish to become pregnant or pregnancy <13 weeks of gestational age.
- BMI > 30 kg/m2 or 18-25 kg/m2
- Understanding of Dutch in speaking and reading
- Willingness to give written informed consent
Exclusion criteria
- Age < 18 years and > 45 years.
- ≥13 weeks of gestational age
- Multiple pregnancy
- Smoking
- Gastro-intestinal diseases, heart diseases, liver, pancreas and kidney diseases.
- Use of antibiotics < 2 weeks before sampling
- Pre-existent diabetes mellitus
Trial design
110 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Nicole Schenkelaars, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal